Erasmus

Mission Bio Announces Launch of Single-Cell Measurable Residual Disease (MRD) Assay Aimed to Advance Personalized Healthcare for Blood Cancer Patients

Retrieved on: 
Tuesday, September 26, 2023
Translation, DNA, Science Advances, Multiple myeloma, NGS, Bone marrow, Clinical trial, Erasmus MC, Biomarker, Erasmus, Doctor of Philosophy, Acute myeloid leukemia, B cell, MRD, AOC, AML, MD, Translational research, Patient, Tapestry lawn, SAN, European, Flow cytometry, Medicine, MSK, MM, Recurrence, Gene, Vaccine, Medical imaging

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 /PRNewswire/ -- Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced the commercial launch of the Tapestri® Single-cell MRD (scMRD) AML Multiomics Assay. The company designed the scMRD AML Multiomics Assay to bring unprecedented resolution to disease relapse and recurrence in acute myeloid leukemia (AML), demonstrating the potential of single-cell DNA and protein multiomics to identify therapeutic targets in recurrent AML.

Key Points: 
  • Tapestri could transform care with comprehensive MRD detection for potentially guiding targeted treatments in AML, multiple myeloma (MM), and other blood cancers."
  • "Relapse continues to be a major challenge in cancer care, especially in the treatment of patients with AML.
  • "Mission Bio's unique approach to characterizing MRD could dramatically change how we stratify patients in clinical trials and create personalized care strategies in the future."
  • The researchers found that the assay could detect clinically relevant variants missed by bulk next-generation sequencing with 0.01% limit of detection.

Highlights - Presentation of CULT implementation reports - Committee on Culture and Education

Retrieved on: 
Thursday, August 31, 2023
CULT, Committee, European Parliamentary Research Service, European Solidarity Corps, Culture, European Parliament Committee on Culture and Education, EIA, Education, Erasmus, Creative Europe, Citizenship

Presentation of CULT implementation reports

Key Points: 
  • Presentation of CULT implementation reports
    On 19 September 2023 the Committee on Culture and Education will present draft implementation reports of the following programmes: Erasmus+ Programme 2021-2027, Creative Europe Programme 2021-2027, European Solidarity Corps programme 2021-2027 and Citizens, Equality, Rights Values programme 2021-2027 (citizens' engagement and participation).
  • To support the work of the CULT committee on its implementation reports, the European Parliamentary Research Service has prepared a European implementation assessment (EIA).
  • The study (EIA) provides an initial evaluation of the implementation of the Erasmus +, Creative Europe, European Solidarity Corps, and Citizens, Equality, Rights and Values Strand 3 funding programmes since their launch in late 2021.
  • For more information, please visit the dedicated webpage.

The Stone Soup Leadership Institute Announces its 2023 Progress Report on The State of Climate Education in U.S., Europe & South Asia

Retrieved on: 
Friday, June 30, 2023
National Center for Atmospheric Research, Ministry of Ecological Transition (France), COP25, National Center for Science Education, Erasmus, Legislation, Education, Political constitution, Teaching, Curriculum, Article, UNICEF, Science education, Ministry, School, Philosophy, Climate change, U-Report, NOW, Renewable energy, Nursing, Forestry, Tutoring

Progress Report : Climate Education in the U.S.

Key Points: 
  • Progress Report : Climate Education in the U.S.
    New Jersey and Connecticut are the first states to legislate a mandate requiring schools to teach climate education.
  • Spain's role as the host of COP25 prompted the creation of additional public climate change education programs, including PAEAS.
  • SOUTH ASIA: In a regional U-Report poll on South Asian countries by UNICEF, it was found:
    65% learned about climate change in school.
  • Survey results of 36 European countries on climate education by Eramus, School Education Gateway (2020):
    The responsibility of climate education lies with schools.

AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research

Retrieved on: 
Tuesday, June 27, 2023
PDAC, Pancreatic cancer, DNA, Toll-like receptor 3, AIM, Neoplasm, Epithelium, RNA, Food and Drug Administration, Clinical trial, Cell proliferation, Erasmus MC, Cancer, Research, FOLFIRINOX, Erasmus, Doctor of Philosophy, Messenger, NYSE, American Journal of Cancer Research, American Journal, Patent, MD, Patient, European Medicines Agency, Immunohistochemistry, Netherlands Patent Office, Food, Safety, Pharmaceutical industry, Rintatolimod

AIM has been granted U.S. Food and Drug Administration orphan drug designation status and European Medicines Agency orphan medicinal product designation status for Ampligen in the treatment of pancreatic cancer.

Key Points: 
  • AIM has been granted U.S. Food and Drug Administration orphan drug designation status and European Medicines Agency orphan medicinal product designation status for Ampligen in the treatment of pancreatic cancer.
  • AIM CEO Thomas K. Equels states: “We remain committed to establishing a new standard of care for pancreatic cancer where there remains a significant unmet need.
  • The data generated to date, including the findings from this pre-clinical study, continue to bolster our confidence in the potential of Ampligen for the treatment of pancreatic cancer.
  • These positive results provide further validation as we continue to focus on advancing our pancreatic cancer development program and execute on our path forward.”

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Can

Retrieved on: 
Tuesday, June 27, 2023
Pancreatic cancer, Response evaluation criteria in solid tumors, AIM, Therapy, IV, Competence, RECIST, DLT, Erasmus MC, Toxicity, Research, FOLFIRINOX, Erasmus, Doctor of Philosophy, AstraZeneca, Trial of the century, NYSE, Competent authority, MD, Patient, Central committee, Durvalumab, AIM ImmunoTech, Disease, Safety, Nootropic, Pharmaceutical industry, Rintatolimod

OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel and potentially powerful therapeutic in locally advanced pancreatic cancer (“LAPC”) and metastatic pancreatic cancer, today announced the required approvals from the Netherlands for Erasmus Medical Center (“Erasmus MC”) to begin a Phase 1b/2 study under the previously announced external sponsored collaborative clinical research agreement with AstraZeneca and Erasmus MC.

Key Points: 
  • The primary objective of the Phase 1b portion of the study is to determine the safety of combination therapy with durvalumab and Ampligen.
  • The primary objective of the Phase 2 portion of the trial is to determine the clinical benefit rate of combination therapy with durvalumab and Ampligen.
  • Patients will start with Ampligen 200mg via IV infusion twice per week for a total of 6 weeks (12 doses).
  • After two doses of Ampligen, the first dose of durvalumab 1500mg via IV infusion will be introduced in week 2.

SAS accelerates responsible innovation efforts with new collaborations and a focus on trustworthy AI

Retrieved on: 
Tuesday, May 9, 2023
Housing, Coalition, ICAI, Microsoft, Privacy, Future, SAS, Computer ethics, MD, Patient, Data, Artificial intelligence, Government, Health, Roadmap, Data science, Software, CHAI, Human, Delft University of Technology, Townsend, Erasmus MC, Research, Erasmus, Organization, Operating, Patient safety, Machine learning, Ethics, Safety, National Innovation Center, AUC, Trust (social science), ChatGPT, Medicine, Intensive care medicine, Good, Business Roundtable, National academy, Explainable artificial intelligence, Bias, Customer service, Medical device, Nursing, Satellite navigation device, AI

ORLANDO, Fla, May 9, 2023 /PRNewswire/ -- SAS INNOVATE -- The world has seen unprecedented artificial intelligence (AI) advances since AI and analytics company SAS launched its responsible innovation efforts one year ago. Amid this rapid disruption, SAS has increased efforts to bring trustworthy AI to customers, including a first-of-its-kind ethical AI health care lab in the Netherlands. SAS also expanded its Data Ethics Practice by integrating its successful Data for Good program, allowing the company to consider not just the risks of AI but also its potential to improve the world.

Key Points: 
  • Amid this rapid disruption, SAS has increased efforts to bring trustworthy AI to customers, including a first-of-its-kind ethical AI health care lab in the Netherlands.
  • As part of its commitment to responsible innovation , SAS partners with organizations globally to explore ways to implement ethical AI within industries.
  • SAS Viya includes trustworthy AI capabilities like bias detection, explainability, decision auditability, model monitoring, governance and accountability, increasing confidence in government agencies' responsible AI efforts.
  • SAS contributed to the Business Roundtable's Roadmap for Responsible Artificial Intelligence, which guides American businesses, policymakers and regulators on their shared journey toward responsible AI.

Erasmus Prize 2023 awarded to Trevor Noah

Retrieved on: 
Thursday, March 16, 2023
Cynic, Racism, Praemium Erasmianum Foundation, Black Lives Matter, The Daily Show, Erasmus, Black, Erasmus Prize, In Praise of Folly, Apartheid, Life, Violence, Born a Crime, COVID-19, Autobiography, Social, Colonialism, History, Humour, Child, Laughter, News, Humanities, Entertainment, Film industry, African, Noah

AMSTERDAM, March 16, 2023 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2023 to the South African comedian Trevor Noah (b.

Key Points: 
  • AMSTERDAM, March 16, 2023 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2023 to the South African comedian Trevor Noah (b.
  • With his sharp-minded, mocking yet inclusive political comedy, Noah, in the eyes of the jury, upholds the 'Erasmian Spirit.'
  • The Erasmus Prize is awarded annually to a person or institution that has made an exceptional contribution to the humanities, the social sciences or the arts.
  • The Erasmus Prize consists of a prize of €150,000.

Erasmus Prize 2023 awarded to Trevor Noah

Retrieved on: 
Thursday, March 16, 2023
Cynic, Racism, Praemium Erasmianum Foundation, Black Lives Matter, The Daily Show, Erasmus, Black, Erasmus Prize, In Praise of Folly, Apartheid, Life, Violence, Born a Crime, COVID-19, Autobiography, Social, Colonialism, History, Humour, Child, Laughter, News, Humanities, Entertainment, Film industry, African, Noah

AMSTERDAM, March 16, 2023 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2023 to the South African comedian Trevor Noah (b.

Key Points: 
  • AMSTERDAM, March 16, 2023 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2023 to the South African comedian Trevor Noah (b.
  • With his sharp-minded, mocking yet inclusive political comedy, Noah, in the eyes of the jury, upholds the 'Erasmian Spirit.'
  • The Erasmus Prize is awarded annually to a person or institution that has made an exceptional contribution to the humanities, the social sciences or the arts.
  • The Erasmus Prize consists of a prize of €150,000.

Qure.ai Awarded EU MDR Certification for Its AI solutions

Retrieved on: 
Wednesday, February 22, 2023
Technology, Surgery, Neurology, Health Technology, Software, Radiology, Health, Data Management, Oncology, Artificial Intelligence, Safety, Human musculoskeletal system, Artificial intelligence, CE, Medical imaging, Erasmus, MDR, Patient, AI, Certification, ER, Erasmus MC, Stroke, Lung cancer, Medical device, EU

Receiving EU MDR certification is a testament to the continued quality of our solutions, and it further strengthens our position as a trusted provider of AI software.

Key Points: 
  • Receiving EU MDR certification is a testament to the continued quality of our solutions, and it further strengthens our position as a trusted provider of AI software.
  • The EU MDR certification will allow us to expand our reach in the EU market and enable better patient outcomes with our imaging AI solutions.
  • EU MDR certification process is rigorous and comprehensive, ensuring that medical devices meet high safety, performance, and quality standards.
  • The MDR certification recognizes the safety, performance, and quality of Qure.ai's AI software and confirms its compliance with EU medical device regulations.

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

Retrieved on: 
Tuesday, January 17, 2023
Degenerative disease, Disease, TLR3, AIM ImmunoTech, B cell, Cancer, AIM, Ovarian cancer, Nootropic, COVID-19, Erasmus, Melanoma, MD, Erasmus MC, Pancreatic cancer, Tumor microenvironment, NYSE, AstraZeneca, Immune system, Therapy, Patient, Triple-negative breast cancer, Research, PD-L1, PD-1, Pancreas, Doctor of Philosophy, Durvalumab, Pharmaceutical industry, Rintatolimod

DURIPANC Study,” in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech.

Key Points: 
  • DURIPANC Study,” in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech.
  • In the previously conducted human clinical studies, Ampligen has shown synergistic potential with PD-1 checkpoint blockade therapeutics.
  • van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, added, “PD-L1 expression levels in the malignant tumors of pancreatic cancer patients correlates to poor prognosis.
  • Additionally, there is published data from two recent clinical studies – in triple-negative breast cancer and advanced recurrent ovarian cancer – that further support Ampligen’s potential to enhance checkpoint blockade therapy efficacy.